

LIST OF TABLES

LIST OF EXHIBITS

CHAPTER TWO: UNDERSTANDING HEALTH CARE REFORM

TABLE 21

STATUS OF ACTION ON MEDICAID EXPANSION, AUGUST 2013

TABLE 21

IMPLEMENTATION OF SELECTED PPACA PROVISIONS BY YEAR

TABLE 23

POPULATION DISTRIBUTION BY AGE, 1990, 2000, 2010 AND 2020

CHAPTER THREE: THE U.S. IVD MARKET AND IMPACT OF REFORM

TABLE 31

TYPES OF IVD AND CLINICAL LAB TESTS, 2013

TABLE 32

U.S. SALES OF IVD AND CLINICAL LAB TESTS, 2012 – 2022, IN \$MILLION

TABLE 33

IMPACT OF PPACA SALES DRIVERS ON U.S. SALES OF IVD AND CLINICAL LAB TESTS, 2012 – 2022

FIGURE 31

IMPACT OF PPACA SALES DRIVERS ON U.S. SALES OF IVD AND CLINICAL LAB TESTS, 2012 – 2022

TABLE 34

IMPACT OF PPACA SALES RESTRAINTS ON U.S. SALES OF IVD AND CLINICAL LAB TESTS, 2012 – 2022

FIGURE 32

IMPACT OF PPACA SALES RESTRAINTS ON U.S. SALES OF IVD AND CLINICAL LAB TESTS, 2012 – 2022

TABLE 35

U.S. PROCEDURE VOLUME FOR IVD AND CLINICAL LAB TESTS, 2012 – 2022

TABLE 36

IMPACT OF PPACA DRIVERS ON U.S. PROCEDURE VOLUME FOR IVD AND CLINICAL LAB TESTS, 2012 – 2022

FIGURE 33

IMPACT OF PPACA DRIVERS ON U.S. PROCEDURE VOLUME OF IVD AND CLINICAL LAB TESTS, 2012 – 2022